Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2020-003201-54 | Registry Identifier | IDRCB number. French competent authority : ANSM |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| RCTs | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Lumbar belt benefit compared to the usual care in the treatment of non-specific low back pain -an interventional, prospective, multicenter, randomized, open and controlled.study
This is a controlled study, with randomization of the patients, which aims at evaluating the benefit and interest of wearing a new generation lumbar belt, in patients suffering from non-specific low back pain. This trial is also designed to provide quality of life data and to assess the medico-economic interest of wearing such a lumbar belt.
This is an interventional study with low risks and constraints that does not deviate from the local standard of care for enrolled patients. No invasive examination or procedure is performed; as such, there will be no additional risks for participating patients.
203 patients will be followed during 12 weeks in up to 20 investigational sites Patients meeting all eligibility criteria will be included in the study and randomized into one of the two following groups on a 1: 1 ratio.
Three visits will be performed:
At inclusion visit, after verification of the eligibility criteria, data regarding patients will be collected: demographic data, low back pain history, medical and surgical history, concomitant medications.
At each visit will be performed:
Patients will be asked to complete on-line questionnaires, following visits and each week.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control group "usual care" | No Intervention | Promotion of physical activity and taking usual medicines for pain relief | |
| Intervention group : lumbar belt | Experimental | wearing the LombaStab belt during 3 months in addition to usual care (promotion of physical activity and taking usual medicines for pain relief). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| LombaStab belt | Device | Instruction given to the patient will be to wear the LombaStab belt from 4 to 8 hours per days, over the whole duration of the study (12 weeks). The investigator will explain to the patient how to adjust it. The LombaStab belt will be equiped with thermosensor to evaluate the belt wearing time at the end of the study. |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline ODI score (Oswestry Disability Index) at 12 weeks | The functional capacity is measured by ODI score.The ODI questionnaire consists in 10 questions and 6 answers modalities.The ODI score results are expressed in percentage.The higher the percentage is, the more the functional capacity is impaired. | Week: 0 and 12 |
| Measure | Description | Time Frame |
|---|---|---|
| Evolution of functional capacity | The functional capacity is measured by ODI score.The ODI questionnaire consists in 10 questions and 6 answers modalities.The ODI score results are expressed in percentage.The higher the percentage is, the more the functional capacity is impaired. | Week: 0 and 4 |
| Evolution of pain level |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Laurent GRANGE, MD, PH | CHU de Grenoble Alpes | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU Grenoble Alpes | Grenoble | France | ||||
| Hôpital Cochin |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D017116 | Low Back Pain |
| D010349 | Patient Compliance |
| ID | Term |
|---|---|
| D001416 | Back Pain |
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
Not provided
Not provided
An interventional, prospective, multicenter, randomized, open and controlled study
Not provided
Not provided
Not provided
Not provided
|
Pain level is measured by NRS scale completed by the patient : minimum, maximum, mean at effort and at rest : 0 corresponds to no pain (better outcome) and 10 to maximum pain (worst outcome) |
| Week: 0, 4 and 12 |
| Evolution of pain characteristics | Characteristics of pain are evaluated by specific questions regarding the description of pain | Week: 0, 4 and 12 |
| Evolution of Quality of Life | Quality of life is measured by the EQ5D questionnaire completed by the patient. The EQ-5D questionnaire has two components: health state description and evaluation. In the description part, health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Mobility dimension asks about the person's walking ability. Self-care dimension asks about the ability to wash or dress by oneself, and usual activities dimension measures performance in "work, study, housework, family or leisure activities". In pain/discomfort dimension, it asks how much pain or discomfort they have, and in anxiety/depression dimension, it asks how anxious or depressed they are. The respondents self-rate their level of severity for each dimension using five-level (EQ-5D-5L) scale. In the evaluation part, the respondents evaluate their overall health status using the visual analogue scale (EQ-VAS). | Week: 0 and 12 |
| Assessment of doctors' opinion on improving the patient's health condition caused by low back pain and severity | Improvement and severity are measured by the CGI-I and CGI-S questionnaires respectively. Doctors' opinion on the change of patient's health condition due to low back pain is measured by the Clinical Global Impression - Improvement questionnaire. The scale has 7 levels of answer from "very strongly improved" which is the better outcome (= 1 point) to "very strongly aggravated" which is the worst outcome (= 7 points) .Intermediate levels are: " Significantly improved "(= 2 points) ; " Slightly improved " (= 3 points) ; " No improvement " (=4 points) ; " Slightly worsen " (=5 points) ; " Seriously worsen" ( = 6 points). The highest score corresponds to the most impairment in quality of life. | Week 0, 4 and 12 |
| Assessment of patient's opinion on Global Impression of Change about his general condition | Improvement is measured by the PGI-C questionnaire. Patient's opinion on Global Impression of Change about her general condition is measured by the modified PGI-C questionnaire (Patient's opinion on Global Impression of Change). The scale has 7 levels from "no change or condition has got worsed"(worse outcome) to "a great deal better, and a considerable improvement that has made all the difference ( better outcome)". Intermediate levels are: "almost the same, hardly any change at all"; "a little better, but no noticeable change", "somewhat better, but the change has not made any real difference"; "moderately better, and a slight but noticeable change"; "better, and a definite improvement that has made a real and worthwhile difference. | Week: 4 and 12 |
| Evolution of spinal mobility vie Finger to floor distance test | Spinal mobility is measured by finger-to-floor distance test. The subject stands erect on a platform 20-cm high He's asked to bend forward as far as possible, while maintaining the knees, arms, and fingers fully extended. The vertical distance between the tip of the middle finger and the platform is measured with a suppletape measure in centimeters. The vertical distance between the platform and tip of the middle finger is positive when the subject do not reach the platform and negative when he can go further. | Week: 0, 4 and 12 |
| Evolution of spinal mobility via Schober Mac Rae test | Spinal mobility is measured by Schober Mac Rae test. The Patient is standing, examiner marks both posterior superior iliac spine and then draws a horizontal line at the centre of both marks. A second line is marked 5 cm below the first line. A third line is marked 10 cm above the first line. Patient is then instructed to flex forward as if attempting to touch his/her toes, examiner remeasures distance between the top and bottom line. | Week: 0, 4 and 12 |
| Evolution of physical activity | Physical activity is measured by IPAQ questionnaire completed by the patient The IPAQ questionnaire measures the time associated to intensive activity, moderate activity, walking and sitting in the last week. | Week: 0, 4 and 12 |
| Evolution of drug consumption | Drug consumption (analgesics, anti-inflammatories, etc), is recorded by the patient each week in ePRO (name of the drug, frequency of taking the medication) | Week: 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 |
| Medical and paramedical consultations | Number of consultations (physiotherapy / doctors / osteopathy…) or hospitalization and complementary examinations carried out are measured by patient's interview | Week: 0, 4 and 12 |
| Duration of Sick leave | Global duration of sick leave (number of days, Saturday and Sunday included) is measured by patient's interview | Week: 0, 4 and 12 |
| Assessment of tolerance | Tolerance is measured by adverse events reported. Number and type of serious and non-serious Adverse Device Effects (ADE) are reported.. | Week: 4 and 12 |
| Assessment of time of belt's wearing | Compliance is measured by a thermosensor specific device fixed to the belt | through study completion, an average of 12 weeks |
| Assessment of patient's satisfaction about the lumbar belt comfort and design | Satisfaction is measured by a specific questionnaire completed by the patient. Questions are about comfort, easy to use, performance on pain, aesthetic... | Week 12 |
| Paris |
| France |
| CHU de St Etienne | Saint-Etienne | France |
| D013568 |
| Pathological Conditions, Signs and Symptoms |
| D010342 | Patient Acceptance of Health Care |
| D000074822 | Treatment Adherence and Compliance |
| D015438 | Health Behavior |
| D001519 | Behavior |